Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tofacitinib - Pfizer

Drug Profile

Tofacitinib - Pfizer

Alternative Names: Cp-690,550; CP-690550; Jaquinus; Tasocitinib; Tofacitinib citrate; Xeljanz; Xeljanz XR

Latest Information Update: 01 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Johns Hopkins University; Oregon Health & Science University; Pfizer; University of Michigan
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants; Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase III Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis
  • Phase II Atopic dermatitis
  • Phase I/II Diffuse scleroderma
  • Phase I Pulmonary sarcoidosis
  • No development reported Dermatomyositis
  • Discontinued Asthma; Crohn's disease; Dry eyes; Irritable bowel syndrome; Renal transplant rejection

Most Recent Events

  • 08 Jun 2020 Pfizer plans a phase II trial in Rheumatoid arthritis (Treatment-experienced, Combination therapy) in May 2020 (PO) (NCT04413617)
  • 04 Jun 2020 Pfizer plans a phase II trial in Pneumonia (In Adults, In Older adults, Combination therapy, In patients with COVID-19) in May 2020 (NCT04412252)
  • 01 Jun 2020 Phase-II clinical trials in Rheumatoid arthritis (Monotherapy, Treatment-experienced) in Sweden and Hungary (PO) (EudraCT2019-002676-14)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top